Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences Development milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus’ pivotal FELIX Phase 2 trial, announced in a separate press release...

Autolus Therapeutics announces the appointment of Dr. William D. Young as a Non-Executive Director LONDON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform – One of the largest private financings of a UK biotech company, and the largest from a single source – continues Blackstone conviction in the country – Durability and favorable toxicity profile of...